CIK 0001623526
- Non-accelerated filer
- Smaller reporting company
Stoke Therapeutics, Inc.
Sign in to watch- Ticker
- STOK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 471144582
- Phone
- +1 781-430-8200
- Business address
- 45 WIGGINS AVENUE, BEDFORD, MA, 01730
- Former names
- ASOthera Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $403,975
- in 4 filings, $404K under 10b5-1 plans
Net −$403,975. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-01 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −20,000 | 71,889 | ||
| 2020-06-01 | Nash Huw M. COO & CBO | Exercise or conversion | +2,107 | $2.19 | $5K | 2,107 |
| 2020-06-01 | Nash Huw M. COO & CBO | Sale | −1,607 | $27.08 | $44K | 500 |
| 2020-06-01 | Nash Huw M. COO & CBO | Sale | −500 | $27.48 | $14K | 0 |
| 2020-06-01 | Nash Huw M. COO & CBO | Exercise or conversion · Employee Stock Option (Right to Buy) | −2,107 | 228,711 | ||
| 2020-05-22 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +7,500 | $0.60 | $5K | 21,000 |
| 2020-05-22 | Liau Gene EVP Research & Preclinical Dev | Sale | −7,500 | $30.00 | $225K | 13,500 |
| 2020-05-22 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 134,066 | ||
| 2020-03-31 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 141,566 | ||
| 2020-03-31 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion | +7,500 | $0.60 | $5K | 13,500 |
| 2020-03-31 | Liau Gene EVP Research & Preclinical Dev | Exercise or conversion · Employee Stock Option (right to buy) | +7,500 | 141,566 | ||
| 2020-03-25 | Walker Robin A. Chief Legal Officer, CCO & Sec | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-03-25 | Tulipano Stephen J CFO | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-03-25 | Ticho Barry Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-03-25 | Liau Gene EVP Research & Preclinical Dev | Grant or award · Employee Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2020-03-25 | Kaye Edward M. MD CEO | Grant or award · Employee Stock Option (Right to Buy) | +197,000 | 197,000 | ||
| 2020-03-25 | Nash Huw M. COO & CBO | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-03-02 | Nash Huw M. COO & CBO | Exercise or conversion | +6,324 | $0.40 | $3K | 6,324 |
| 2020-03-02 | Nash Huw M. COO & CBO | Exercise or conversion | +42,779 | $2.19 | $94K | 49,103 |
| 2020-03-02 | Nash Huw M. COO & CBO | Sale | −33,148 | $25.66 | $851K | 15,995 |
Page 32 of 35 · 681 trades